{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-002398","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2022-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.585530+00:00","generated_at":"2026-06-25T00:53:48.341859+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entera Bio President of R&D & Director resigns under separation deal with cash and option benefits","bullets":["Dr. Phillip Schwartz resigns as President of R&D (effective July 21, 2022) and from Board (immediate); no disagreement.","Cash separation payment of ~$155,900 plus ~$213,952 in accrued benefits; also fully accelerated 100,000 option shares subject to shareholder approval.","Proposed consulting agreement for business development services with 14-day termination notice.","Schwartz agrees to non-disparagement, mutual release, and voting/standstill restrictions until after 2023 AGM."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-002398","json":"https://secwatch.observer/filing/0001178913-22-002398.json","markdown":"https://secwatch.observer/filing/0001178913-22-002398.md","text":"https://secwatch.observer/filing/0001178913-22-002398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:53:48.341859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b43ce5d354","claim":"Phillip Schwartz resigned as Director at Entera Bio Ltd..","evidence_excerpt":"would resign from the Company’s Board of Directors (the “Board”), effective as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d7acab6e83","claim":"Phillip Schwartz resigned as President of Research & Development at Entera Bio Ltd..","evidence_excerpt":"Dr. Schwartz would resign from his position as the Company’s President of R&D, effective July 21, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President of Research & Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}